Edition:
United Kingdom

ESSA Pharma Inc (EPIX.OQ)

EPIX.OQ on NASDAQ Stock Exchange Capital Market

3.90USD
21 Jun 2018
Change (% chg)

$-0.10 (-2.50%)
Prev Close
$4.00
Open
$3.81
Day's High
$3.90
Day's Low
$3.81
Volume
200
Avg. Vol
3,702
52-wk High
$13.00
52-wk Low
$2.78

Chart for

About

ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen... (more)

Overall

Beta: --
Market Cap(Mil.): $10.60
Shares Outstanding(Mil.): 29.10
Dividend: --
Yield (%): --

Financials

  EPIX.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -0.31 -- --
ROI: -82.10 2.00 14.38
ROE: -1,251.29 3.49 16.08

BRIEF-Essa Pharma Files For Resale Of 113.9 Mln Common Shares By Selling Shareholders

* ESSA PHARMA INC FILES FOR RESALE OF CO'S 113.9 MILLION COMMON SHARES BY SELLING SHAREHOLDERS - SEC FILING Source: (http://bit.ly/2Ft0Xh1) Further company coverage:

06 Mar 2018

BRIEF-Essa Pharma Qtrly Loss Per Share $0.07

* ESSA PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FINANCIAL RESULTS FOR FISCAL FIRST QUARTER ENDED DECEMBER 31, 2017

13 Feb 2018

BRIEF-Essa Pharma Files For Offering Of About 113.9 Million Common Shares That May Be Offered For Resale By Selling Shareholders

* ESSA PHARMA INC FILES FOR OFFERING OF ABOUT 113.9 MILLION COMMON SHARES THAT MAY BE OFFERED FOR RESALE BY SELLING SHAREHOLDERS - SEC FILING Source text: (http://bit.ly/2Dsiula) Further company coverage:

22 Jan 2018

BRIEF-Bvf Partners Reports 9.9 Percent Passive Stake In Essa Pharma‍​

* BVF PARTNERS L.P REPORTS 9.9 PERCENT PASSIVE STAKE IN ESSA PHARMA INC AS OF JANUARY 5, 2018 - SEC FILING ‍​ Source text - http://bit.ly/2DgNTLE Further company coverage:

16 Jan 2018

BRIEF-Essa Says Intends To Issue Up To 125 Mln Common Shares At $0.20 Per Share

* ESSA ANNOUNCES FILING OF AMENDED AND RESTATED PROSPECTUS SUPPLEMENT AND AN UPDATE TO PREVIOUSLY ANNOUNCED EQUITY OFFERING

03 Jan 2018

Earnings vs. Estimates